Heightened Immune Activation in Fetuses with Gastroschisis May Be Blocked by Targeting IL-5

Human fetal immune development is a critical component of pre- and postnatal health, yet the environmental factors governing normal immune ontogeny remain poorly understood. There is a growing understanding of prenatal factors that may impact immune development. For example, exposure to retinoic acid is important in the development of lymphoid tissue inducer cells (1). Furthermore, increasing evidence indicates that the fetal adaptive immune system is more sophisticated than previously recognized. For example, the neonatal intestine contains memory T cells that may facilitate mother-to-child HIV transmission (2), and circulating neonatal T cells can contribute to ongoing inflammation by producing chemokines such as IL-8 (3). However, whether and how fetal immune development is altered in patients with birth defects that change this developmental milieu are not understood.

Gastroschisis is a congenital defect of the abdominal wall that results in exposure of the intestines to amniotic fluid during development. Although the etiology is not known, gastroschisis is characterized by inflammation of the exposed intestines, with resultant bowel damage (4). Because this defect develops early in gestation, it represents a natural model in which to examine the consequences of chronic inflammation on the development of systemic and tissue-resident fetal immune cells. Several groups have examined amniotic fluid from these pregnancies and found higher levels of IL-6 and IL-8, with concomitant increases in mononuclear cells and neutrophils in patients with gastroschisis compared with controls (5, 6). The current understanding of this disease is that exposure to the inflammatory cytokines in amniotic fluid, in addition to possible ischemic damage from a small abdominal wall defect, activates an innate immune response in the serosa of the exposed intestine. However, systemic immune changes in the fetus have not yet been examined.

Studying immune changes in gastroschisis has important clinical relevance. Pregnancies affected with fetal gastroschisis can have multiple complications such as low fetal weight, in utero fetal demise, or preterm delivery (7, 8). Although the intestines can be placed back into the abdomen after birth, neonates with gastroschisis often suffer from poor intestinal motility after this operation and spend at least several weeks in the neonatal intensive care unit until the bowel recovers enough to tolerate enteral feeds. It is possible that alterations in fetal immune development may play a role in these related problems and, if so, targeted treatments could be developed.

To explore the potential roles of prenatal inflammation and fetal immune activation in gastroschisis, we examined cytokine profiles and relevant cell types in cord blood and intestines of neonates with this disease. We also used a genetic mouse model of gastroschisis (9) to confirm these findings and to test fetal treatment strategies. Our results indicate significant changes in both innate and adaptive immune cell development in gastroschisis, which may impact downstream complications in these patients. Importantly, we demonstrate that some of these changes can be reversed with fetal therapy.

Mothers carrying unaffected fetuses, those with gastroschisis, or those with a large omphalocele (an abdominal wall defect in which the intestines are covered with amnion and do not exhibit inflammation) were prospectively enrolled between November 2009 and December 2012. The Institutional Review Board at the University of California approved the study and written informed consent was obtained.

Samples of cord blood were collected at the time of birth and maternal blood was collected within 24 h of delivery. Plasma was frozen and stored for batch analysis of cytokines. PBMCs were isolated by Ficoll-Paque Plus density gradient centrifugation, frozen, and analyzed in batches during the study period.

Cytokine profiles in the maternal and cord blood plasma samples were assayed using the standard-sensitivity Milliplex Map kit (Millipore) as previously reported (10). Samples were acquired and analyzed on a LABScan 100 analyzer (Luminex) using Bio-Plex manager 6.0 software (Bio-Rad).

The University of California San Francisco pathology database was queried after Institutional Review Board approval to identify patients with gastroschisis who underwent bowel resection between February 2004 and April 2012. Patients who underwent surgical resection secondary to intestinal obstruction or atresia (and not bowel necrosis) and had a lymphocytic infiltrate on H&E stain were identified for further analysis and immunostaining. Control specimens were obtained from patients undergoing autopsy for birth asphyxia or surgical resection specimens from patients without gastroschisis, taking unaffected portions of intestine. Sections (5 μm) from formalin-fixed, paraffin-embedded tissues were stained using an Ab against human CD3 (F7.2.38; Dako) and counterstained with hematoxylin to identify T cells. Eosinophils were identified using H&E staining (11). Cell counts were performed on random high-power fields, excluding areas of lymphoid follicles, by a pathologist (A.N.M.) blinded to patient group. Fresh bowel specimens were collected from surgical procedures in three gastroschisis patients and four controls. The intraepithelial lymphocytes (IELs) and lamina propria lymphocytes (LPLs) were isolated from the mucosa and submucosa, respectively, as previously described (12). The mucosa was dissected from the muscular layer and washed with 1 mM dl-DTT followed by 5 mM EDTA to isolate IELs. The remaining tissue was mechanically dissociated and then digested with 0.1 mg/ml collagenase to harvest LPLs.

Aortic carboxypeptidase-like protein (ACLP)^+/− mice (9) were obtained from Dr. Matthew Layne (Harvard Medical School). Mice were bred and maintained in a specific pathogen-free facility at the University of California San Francisco. All mouse experiments were performed according to the University of California San Francisco Institutional Animal Care and Use Committee–approved protocol. ACLP^+/− mice were bred to each other and all pups were harvested at embryonic day (E)18.5. Lymphocytes were isolated from spleens, livers, and intestines of ACLP^−/− pups with gastroschisis and unaffected littermate controls. Liver was lysed using ACK lysing buffer. Intestine was mechanically dissociated and digested first with 10 mM DTT and then with 1 mg/ml dispase and 100 U/ml DNase I solution.

ACLP^+/− pregnant females were injected i.v. with a neutralizing Ab against IL-5, (TRFK5; BD Pharmingen) or an isotype control (R3-34; BD Pharmingen) for 5 consecutive days, using a dose of 100 μg on E13.5–E14.5 and 150 μg on E15.5–E17.5 fetuses. The amount of Ab was calculated to achieve a fetal dose of 10 mg/kg (the same dose that is typically used in an adult mouse) (13) and an estimated maternal–fetal transmission of 2–3% (14). Fetal intestines and liver were analyzed on E18.5. In the case of fetal intervention, fetuses were injected with the same Abs on E13.5 using a fetal intrahepatic injection as previously described (15–17). Briefly, mothers were anesthetized and the uterus was exposed by performing a laparotomy. The fetuses were injected individually, through the translucent intact uterus, with the neutralizing Ab; controls were injected with the isotype control Ab or PBS in a volume of 5 ml, using pulled glass micropipettes. The laparotomy was closed in layers and the fetuses were analyzed on E18.5.

ACLP^+/− pregnant females were bred to ACLP^+/− males and the fetuses were injected on E13.5 with an anti-Thy1.2 Ab (30H12; Bio X Cell) or isotype control (LTF-2; Bio X Cell) directly into the fetal liver as described above. The pups were harvested on E18.5 and intestines were processed and stained for flow cytometry.

We stained human PBMCs with mAbs to CD3 (UCHT1; BD Biosciences), CD4 (SK3; BD Biosciences), CD8 (SK1; BD Biosciences), CD25 (M-A251; BD Biosciences), CD45RA (ALB11; Beckman Coulter), CCR7 (MAB197; R&D Systems), Helios (22F6; BioLegend), Foxp3 (236A/E7; eBioscience), IL-4 (MP4-25D2; BD Biosciences), IL-17 (eBio64DEC17; eBioscience), IFN-γ (B27; BD Biosciences), and Fixable Viability Dye eFluor 780 (eBioscience). The cytokine-producing capacity of T cell subsets was assessed after PBMCs were stimulated (at a density of 5 × 10⁵ cells ml) for 5 h with 50 ng/ml PMA (Sigma-Aldrich) and 2 μg/ml ionomycin (Sigma-Aldrich) in the presence of 10 μg/ml brefeldin A (Sigma-Aldrich). Cells were fixed and made permeable with the Foxp3/transcription factor staining buffer set (eBioscience) according to the manufacturer’s instructions. For flow cytometric analysis of human intestine, IELs and LPLs were stained with mAbs to CD3 (UCHT1; BD Biosciences), CD4 (SK3; BD Biosciences), CD8 (SK1; BD Biosciences), IL-7Rα (HIL-7R-M21; BD Pharmingen), and c-Kit (104D2; BD Biosciences).

We stained mouse leukocytes with mAbs to CD3 (17A2; BioLegend), TCRβ (H57-597; eBioscience), TCRγ/δ (GL3; BioLegend), CD5 (53-7.3; eBioscience), CD19 (6D5; BioLegend), CD11b (M1/70; BD Pharmingen), CD11c (N418; eBioscience), NK1.1 (PK136; eBioscience), CD45.2 (104; eBioscience), Thy1.2 (53-2.1; BioLegend), CD8a (53-6.7, BD Pharmingen), CD4 (RM4-5; BD Pharmingen), retinoid-related orphan receptor (ROR)γt (B2D; eBioscience), Gata-3 (TWAJ; eBioscience), c-Kit (2B8; eBioscience), IL-7Rα (A7R34; eBioscience), Siglec-F (E50-2440; BD Pharmingen), and Fixable Viability Dye eFluor 780 (eBioscience). All samples were acquired with an LSR II (Becton Dickinson) flow cytometer and analyzed with FlowJo software (Tree Star).

Reagents included Ficoll-Paque Plus (GE Healthcare), ACK lysing buffer (Lonza), dl-DTT (AllStar Scientific), EDTA (Corning cellgro), collagenase (from Clostridium histolyticum; Sigma-Aldrich), Dispase (Life Technologies), and DNase I (bovine pancreas; Roche).

Statistical analysis and graphs were generated using Prism 5 software (GraphPad Software) or Stata version 12 (StataCorp, College Station, TX). Data were analyzed using the Mann–Whitney U test (for nonparametric data), an unpaired t test (for normally distributed data), or a χ² test (to assess the differences in proportion between groups). For multiple categories, one-way ANOVA with a Tukey posttest was applied. For cytokine analysis, a supervised principal component analysis (sPCA) was performed, which used the subset of cytokines that were most correlated with the outcome (Spearman correlation coefficient > 0.25). The Kendall tau-c statistic was also calculated to test the magnitude and direction of increases or decreases in cytokine levels across disease severity groups. A multiple regression analysis was performed to account for the presence of spontaneous preterm labor and maternal smoking (data on smoking was not recorded in the medical record for 2 of 30 controls and 4 of 26 patients with gastroschisis; these patients were analyzed as nonsmokers). A p value <0.05 was considered statistically significant.

We prospectively enrolled 27 patients with gastroschisis and 23 healthy term controls for collection of maternal and cord blood at the time of delivery (Table I). There were no significant differences in nulliparity, mode of delivery, and fetal gender between mothers of healthy controls and those of fetuses with gastroschisis. Mothers of fetuses with gastroschisis were more likely to be younger, experience preterm labor, deliver earlier, and have infants with lower birth weights than were mothers with unaffected pregnancies, as previously reported (7). Other clinical characteristics of patients with gastroschisis are shown in Supplemental Table I.

The amniotic fluid in patients with gastroschisis has increased levels of inflammatory cytokines (5, 6). To determine whether there is evidence of fetal systemic inflammation in this condition, we analyzed serum cytokines in cord blood. We found that fetuses with gastroschisis had significantly elevated levels of eotaxin-1 (CCL11), CXCL1, IL-1Rα, IL-6, IL-8, soluble IL-2Rα, and MCP-1 and decreased levels of macrophage-derived chemokine (MDC) in the cord blood compared with controls (Fig. 1A; results for all cytokines tested and all relevant comparisons are shown in Supplemental Table II). We also performed an sPCA using the plasma biomarkers that were correlated with gastroschisis (those with Spearman correlation coefficient > 0.25; namely, eotaxin, CXCL1, IL-1Rα, IL-6, IL-8, soluble IL-2Rα, MCP-1, MDC, IL-12 [p40], and TGF-α). The first principal component predominantly comprised eotaxin, IL-1Rα, IL-6, IL-8, and MCP-1, and it differed the most between patients and controls (Fig. 1B). Of note, we also analyzed two patients who had a large omphalocele and their cytokine profiles were within the control distribution (Fig. 1B). Thus, there is evidence of systemic inflammation in fetuses with gastroschisis.

Pregnancies with gastroschisis have a higher incidence of spontaneous preterm labor (sPTL) and maternal smoking. To determine whether the observed changes in cytokines were secondary to PTL or maternal smoking, we performed a multiple regression analysis and adjusted for these variables. All of the observed cord blood cytokine changes remained statistically significant even when controlling for PTL and maternal smoking, suggesting these changes are secondary to the underlying disease.

We next asked whether fetal immune development was altered in the context of systemic inflammation. We focused first on T cells, given their role in promoting intestinal inflammation in other settings (18–20). We found that patients with gastroschisis have significantly increased percentages of CD4⁺ and CD8⁺ T cells that produce IFN-γ compared with controls (Fig. 1C, 1D); the increase was most pronounced in CD8⁺ T cells. The numbers of Th17 cells in patients with gastroschisis also increased (Fig. 1E), although their concentration in the blood is usually relatively low (21). These results are consistent with the systemic increase in IL-6, which can control the differentiation of T cells to Th17 cells (21). However, we did not observe a difference in the percentages of IL-4–producing (Th2) fetal T cells (Supplemental Fig. 1A). We also examined the percentages of naive (CD45RA⁺CCR7⁺), central memory (CD45RA⁻CCR7⁺), effector memory (EM, CD45RA⁻CCR7⁻), and terminally differentiated EM (EMRA, CCR7⁻CD45RA⁺) cells (22) and found increased percentages of CD4⁺ EM and CD8⁺ EMRA T cells in patients with gastroschisis; once again, the increases were most pronounced (and likely biologically relevant) among CD8⁺ T cells (Fig. 1F, 1G). When we adjusted for the presence of sPTL, the changes in CD4 and CD8 cells producing IFN-γ and CD8 EM and CD8 EMRA cells remained significant. Finally, given previous reports of the propensity of fetal T cells to differentiate into regulatory T cells (23), we compared percentages of Foxp3⁺Helios⁺ regulatory T cells in patients and controls and found no differences (Supplemental Fig. 1B, 1C). Thus, chronic inflammation in gastroschisis leads to the production of effector T cells without a compensatory regulatory response.

To determine whether there were maternal immune changes in pregnancies affected with gastroschisis, we examined plasma cytokine and blood T cell phenotypes in matched maternal samples collected at the time of delivery. We detected a generalized decrease in cytokine, chemokine, and growth factor levels in women carrying fetuses with gastroschisis compared with controls, with significant decreases in levels of fractalkine, GM-CSF, and IL-12 (p70) (Supplemental Table III). In examining circulating T cell profiles, we detected a significant increase in Th17 cells (Supplemental Fig. 1D), but no differences in the production of IFN-γ by CD4⁺ or CD8⁺ T cells (Supplemental Fig. 1E, 1F) in mothers of gastroschisis patients. However, the increase in Th17 cells was not significant after adjusting for sPTL. We also observed that maternal CD4⁺ EM T cells increased slightly, but CD8⁺ EM and EMRA T cells did not change in pregnancies with gastroschisis (Supplemental Fig. 1G). Thus, immune activation in this disease occurs predominantly on the fetal side.

The systemic increases in activated T cells led us to evaluate whether similar changes could be found locally in the inflamed intestines. Neonates with gastroschisis have an inflammatory peel surrounding the intestine, characterized by subserosal edema, fibrosis, macrophage infiltration, capillary proliferation, and epithelial cell deposition, which develops after 30 wk of gestation (24), but T cell infiltration has not been evaluated. We examined surgical specimens of nonnecrotic intestine in patients with gastroschisis and age-matched controls using H&E, and stained for T cells using an Ab against CD3. We confirmed that the intestine of patients with gastroschisis is characterized by a marked thickening of all layers and serosal vascular proliferation, suggesting chronic ischemic injury (Fig. 2A). T cells were present in the intestinal serosa (Fig. 2B, 2C) and lymphoid follicles in patients with gastroschisis (Fig. 2D), with infiltration beyond the boundaries of these follicles into the submucosa and mucosa, which was not seen in healthy controls. Overall, patients with gastroschisis showed significantly higher numbers of T cells in the intestinal mucosa as well as the serosa (Fig. 2E). Thus, histologic changes in the intestine extend well beyond the serosal surface that is exposed to amniotic fluid and are more consistent with systemic immune alterations.

Because eotaxin-1 was increased in cord blood plasma of patients with gastroschisis, we also examined eosinophils in bowel samples of these neonates. Activated eosinophils have been implicated in intestinal inflammation and dysfunction in other clinical settings (25) but have not been examined previously in this disease. We found that eosinophils were dramatically increased in the intestinal mucosa of patients with gastroschisis compared with age-matched controls (Fig. 2F).

Given the interesting changes in fetal immune development in patients with an abdominal wall defect, we next turned to an appropriate mouse model to validate these findings and test prenatal treatment strategies. Mice lacking ACLP (9) have a spontaneous abdominal wall defect with exteriorized bowel and liver that results in decreased numbers of enteric neurons and interstitial cells of Cajal (26), similar to human gastroschisis (Fig. 3A). To characterize the fetal immune response in this mouse model, we examined cells of both the adaptive and innate immune systems in affected fetuses (ACLP^−/−) and their unaffected littermates (ACLP^+/− and ACLP^+/+) at E18.5. We detected elevated eosinophils (both the percentages and absolute numbers) in the fetal mouse intestine and liver (Fig. 3B, 3C). There were also increased NK cells in the exteriorized liver (Fig. 3D). Importantly, the changes in the affected mice were observed predominantly in herniated organs exposed to amniotic fluid and were not seen in nonherniated organs (Fig. 3C, 3D) or in the spleen (data not shown). T cells were unchanged (data not shown), likely secondary to their delayed maturation in mice compared with humans. Despite differences in the timing of fetal immune development between mice and humans, the finding of altered immune maturation in the mouse indicates that the ACLP^−/− mouse is a suitable model for mechanistic studies on bowel damage in gastroschisis.

Innate lymphoid cells (ILCs) are crucial determinants of fetal immune development (27, 28), especially in the fetal intestine (29). In particular, eosinophil development and survival are mediated by IL-5, the serum levels of which are maintained by tissue-resident ILC2 (30). Because eosinophils were increased in mice with gastroschisis, we examined ILC2 in the intestines of ACLP^−/− mice and found that both percentages and absolute numbers of ILC2 are increased in the exteriorized intestine compared with littermate controls (Fig. 4A, 4B). Another subset of ILCs, ILC3, has been shown to contribute to the inflammatory state of the intestine during pathological conditions (31). Therefore, we analyzed ILC3 and found that both the percentages and absolute numbers of ILC3 (defined as CD45⁺Lin⁻CD3⁻CD4⁺c-Kit⁺IL-7Rα⁺RORγt⁺) (32) were also increased in the exposed intestine (Fig. 4C) and livers (Fig. 4D) of ACLP^−/− mice compared with littermate controls. We also examined ILCs in intestines of neonates with gastroschisis. Our numbers were limited by the rarity of intestinal resection, and therefore of fresh tissues, in these patients, so we performed a general stain for ILCs that includes the different subsets (CD3⁻CD4⁻c-Kit⁺IL-7Rα⁺) (32) after isolating intraepithelial and lamina propria lymphocytes. We detected increased numbers of ILCs in the intestines of patients with gastroschisis compared with controls (Fig. 4E).

We next sought to define a treatment that could address some of the immunologic changes seen in the mouse model of gastroschisis. Because eosinophils and ILC2 were increased in this model, we targeted IL-5 signaling and tested both direct fetal injection and maternal administration of a blocking Ab. We first tested direct fetal administration by injecting fetal mice with TRFK5, a neutralizing Ab against IL-5, or either isotype control or PBS on E13.5–E14.5, using our established fetal intrahepatic injection method (15–17). We then harvested the pups on E18.5 and analyzed the immune cells in exposed and nonexposed organs (Fig. 5A). These experiments showed that all fetuses injected with the isotype control or PBS had high levels of eosinophils, indicating that sterile inflammation from the surgery results in a fetal immune response. However, this rise in eosinophils was mitigated effectively by blocking IL-5 in both the intestine and the liver (Fig. 5B, 5C).

We next examined maternal administration of TRFK5, because this Ab can cross the placenta. Maternal i.v. injections of TRFK5 (or isotype control) were given daily between E13.5 and E17.5, and fetal intestine and liver were harvested on E18.5 (Fig. 5D). This treatment led to a significant decrease in eosinophils compared with isotype control in both the intestine (Fig. 5E) and liver (Fig. 5F). The treatment was effective in reducing eosinophil counts in both gastroschisis and control mice; ILC2s were reduced as well (Fig. 5G).

ILC2s have been implicated in the onset of eosinophilia by producing IL-5 (33). To determine whether there is a mechanistic link between ILC2 and eosinophilia in our model, we depleted fetal ILCs by injecting fetuses with a depleting Ab against Thy1.2 on E13.5 and harvested the pups on E18.5 (Fig. 6A). We detected a significant decrease in the percentages and absolute numbers of ILC2 and eosinophils in the intestines of treated pups compared with those treated with an isotype control (Fig. 6B, 6C). Thus, ILC2 may be involved in recruiting eosinophils to the intestine in gastroschisis. Collectively, our results indicate that targeted prenatal therapies may limit ongoing fetal inflammation and aberrant immune development during prenatal inflammation.

In this study, we examined fetal immune development in the context of ongoing systemic inflammation, using a congenital abdominal wall defect as a model system. We demonstrate that patients with gastroschisis have increased systemic levels of inflammatory cytokines and specific changes in the development of effector T cell subsets. We also characterized changes in mucosal immunity in this disease, including local infiltration of T cells, eosinophils, and ILCs in the affected intestine. These changes were mirrored in the mouse model of gastroschisis and could be ameliorated by administration of an Ab against IL-5 or by depleting ILC2. Systemic changes in prenatal immune development as a result of chronic prenatal inflammation are a novel finding; our work suggests that these changes have consequences for the health of the fetus and neonate but could be reversed with in utero therapy.

Our findings add to the growing literature on human fetal immune development and indicate that the presence of external stressors prenatally can significantly affect the fetal immune system. It has been suggested that the initial insult in gastroschisis is ischemic, secondary to a narrow abdominal wall defect (34), and the cytokine profile we obtained is consistent with the changes reported in the setting of intestinal ischemia-reperfusion injury (35). We speculate that the ischemic insult initiates an inflammatory environment, leading to recruitment and activation of T cells and eosinophils and ultimately resulting in bowel damage. T cells have been found to infiltrate ischemic tissues and produce IL-17, which may mediate tissue damage (36), and T cell depletion can ameliorate intestinal damage in an intestinal ischemia-reperfusion injury model (37). ILC3 and γδ T cells may also contribute to the production of IL-17, although their low numbers in circulation limited our ability to directly examine these cell types (38–40). Our data indicate that IL-5 production by ILC2 is involved in the recruitment of eosinophils in this context, but that prenatal blockade of IL-5 may dampen the fetal immune response.

Epithelial cells contribute to the cytokine milieu that stimulates ILC2 (41-44): thus, it is possible that the intestinal inflammation triggered by gastroschisis induces the expansion of ILC2s. Our data in the mouse model suggest that ILC2 can, in turn, contribute to increased intestinal eosinophilia. However, the role of ILCs in intestinal development is complex and there have also been reports that ILC2s promote tissue repair and homeostasis during inflammation (42, 45). It is possible that in patients with gastroschisis, ILCs may also serve to quell inflammation, particularly because one of the hallmarks of this disease is spontaneous resolution of inflammation over several weeks/months after birth. Finally, because ILCs regulate T cell responses to commensal flora (46), alterations in their development may affect early microbial colonization. Of note, patients with gastroschisis are particularly susceptible to necrotizing enterocolitis, which has been associated with changes in the microbiome (47) as well as dysregulation of intestinal T cells (12).

The present study also adds to our understanding of the pathophysiology of intestinal damage in utero. Increases in tissue-resident eosinophils and T cells have been implicated in intestinal inflammation in other conditions, and there may be similarities in the pathways leading to intestinal damage. For example, activated eosinophils and their granule proteins have been implicated in the pathogenesis of intestinal inflammation in inflammatory bowel disease, with increased levels correlating with worsening disease severity (48, 49). In addition to serving as a chemotactic factor for eosinophils, eotaxin may be involved in recruiting T cells that express the eotaxin receptor CCR3 to the intestine (50) and may adversely affect bowel motility (51). Locally, T cell infiltration and inflammatory cytokine production in the intestines may contribute to bowel dysmotility by multiple mechanisms, including damaging the interstitial cells of Cajal (52), which have been shown to be developmentally delayed in gastroschisis (53).

In addition to implications for the pathophysiology of bowel damage, the immune changes we observed may have implications for the health of the pregnancy. Patients with gastroschisis are susceptible to pregnancy complications such as preterm labor and intrauterine growth restriction and such complications may contribute to the cytokine and T cell profiles we observed in cord blood. Interestingly, all of the cytokine changes and some of the T cell changes remained significantly different when controlling for the presence of sPTL. It is possible that the underlying inflammation in gastroschisis (which is likely sterile, given the low rate of clinical chorioamnionitis observed) results in precocious activation of the fetal immune system and contributes to the onset of PTL (54). It will be interesting to determine the Ag specificity of activated fetal T cells to understand their functional significance. Understanding the consequences of specific fetal immune responses secondary to sterile inflammation (seen with this condition) or during prenatal infections could lead to valuable insights into reproductive immunology.

Although fetuses with gastroschisis are often diagnosed prenatally, there is currently no fetal therapy to decrease intestinal damage. Serial exchange of amniotic fluid has been proposed as a prenatal therapy to relieve bowel inflammation, without robust results (55), likely because there is ongoing fetal production of inflammatory mediators that act at the intestinal level to promote tissue damage. However, systemic treatments targeted at reducing particular cell types in utero may be a more effective option, as demonstrated by our mouse experiments. In this regard, further examinations into the role of IL-5 signaling in the prenatal period may yield clinically relevant therapeutic approaches for this disease.

We thank L. Coniglio, G. Bautista, and S. Trivedi for assistance with sample collection and processing, and our patients for gracious participation in this study. We thank M. Layne (Department of Biochemistry, Boston University School of Medicine, Boston, MA) for providing the ACLP^+/− mice, P. Ursell (Department of Pathology, University of California San Francisco) for providing pathology specimens, and R. Locksley, J. Bando, M. McCune, C. Iqbal, and S. Fisher (University of California San Francisco) for helpful discussions.

The authors have no financial conflicts of interest.